A bitter pill for Glaxo investors
PHARMACEUTICALS MATTHEW CURTIN OF DOW JONES NEWSWIRES
The Business
26 May 2007

IT’S been a terrible few days for GlaxoSmithKline, the British drugs giant. Investors have wiped more than £7bn off its market value because of fears over the safety of its Avandia group of diabetes drugs, one of the firm’s two blockbuster... read more...

Tech Tags: The Business newspaper Global Briefing

In Europe, warning on Avandia is old news
By Jeanne Whalen
The Wall Street Journal Europe
23 May 2007

CONCERNS about the safety of GlaxoSmithKline PLC’s diabetes drug Avandia underscore the different approaches to medical regulation in different markets. A day after U.S. politicians called on the U.S. Food and Drug Administration to strengthen its... read more...

Tech Tags: The Wall Street Journal Europe newspaper Marketplace

Globalisation: Pharma taking the acquisition route
Habil Khorakiwala
Economic Times
14 May 2007

OU could be watching ‘Untamed Africa’ on National Geographic, only it’s a different sort of jungle — the corporate kind. The rules of survival and conquest, however, remain the same. Size matters, but it is not everything. What matters more is whether... read more...

Tech Tags: Economic Times newspaper VIEWPOINT

Simple drug leads to horrific reaction
BY SHARON KIRKEY CanWest News Service
Times Colonist
07 May 2007

Somewhere near Quebec City lives a young mother who spent four weeks in a burn unit last year after a suspected drug reaction covered her body with burn-like red blisters and peeled off her skin from head to thigh. The woman had been prescribed the... read more...

Related:
Sinus drug linked to liver damage, skin peeling

Tech Tags: Times Colonist newspaper Top Stories